Search research articles
Contact Us
Filters
Showing results (211-220 of 220) with videos related to
Page
of 22
Sort By:
You have reached the last page of results.
This site can display upto 220 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 27, 2024
Extent of Lymphadenectomy for Surgical Management of Right-Sided Colon Cancer: The Randomized Phase III RELARC Trial
Junyang Lu, Jiadi Xing, Lu Zang, et al.
BMJ Open
|
September 12, 2023
Long-course chemoradiation plus concurrent/sequential PD-1 blockade as neoadjuvant treatment for MMR-status-unscreened locally advanced rectal cancer: protocol of a multicentre, phase 2, randomised controlled trial (the POLAR-STAR trial)
Kai Pang, Yun Yang, Dan Tian, et al.
Cancer
|
December 9, 2025
Long-term outcomes of ripretinib versus sunitinib in Chinese patients with advanced gastrointestinal stromal tumor: An updated analysis of a phase 2 randomized clinical trial
Jun Zhang, Yanqiao Zhang, Haibo Qiu, et al.
BMC Cancer
|
January 6, 2021
The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial
Xinxin Wang, Shuo Li, Yihong Sun, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu
|
May 25, 2017
Postoperative chemotherapy with S-1 plus oxaliplatin versus S-1 alone in locally advanced gastric cancer (RESCUE-GC study): a protocol for a phase III randomized controlled trial
Xiang Hu, Lin Chen, Yian Du, et al.
The Journal of Clinical Investigation
|
February 8, 2022
An Asia-specific variant of human IgG1 represses colorectal tumorigenesis by shaping the tumor microenvironment
Bing Yang, Zhen Zhang, Xiangjun Chen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 19, 2023
Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China
Jian Li, Jun Zhang, Yanqiao Zhang, et al.
The Lancet. Oncology
|
July 12, 2021
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
Xiaotian Zhang, Han Liang, Ziyu Li, et al.
The Lancet. Oncology
|
February 14, 2025
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial
Xiaotian Zhang, Han Liang, Ziyu Li, et al.
Journal of Hematology & Oncology
|
February 16, 2019
Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition)
Jian Li, Ying Yuan, Fan Yang, et al.
Page
of 22
Search research articles
Search
Showing results (211-220 of 220) with videos related to
Sort By:
Page
of 22
You have reached the last page of results.
This site can display upto 220 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 27, 2024
Extent of Lymphadenectomy for Surgical Management of Right-Sided Colon Cancer: The Randomized Phase III RELARC Trial
Junyang Lu, Jiadi Xing, Lu Zang, et al.
BMJ Open
|
September 12, 2023
Long-course chemoradiation plus concurrent/sequential PD-1 blockade as neoadjuvant treatment for MMR-status-unscreened locally advanced rectal cancer: protocol of a multicentre, phase 2, randomised controlled trial (the POLAR-STAR trial)
Kai Pang, Yun Yang, Dan Tian, et al.
Cancer
|
December 9, 2025
Long-term outcomes of ripretinib versus sunitinib in Chinese patients with advanced gastrointestinal stromal tumor: An updated analysis of a phase 2 randomized clinical trial
Jun Zhang, Yanqiao Zhang, Haibo Qiu, et al.
BMC Cancer
|
January 6, 2021
The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial
Xinxin Wang, Shuo Li, Yihong Sun, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu
|
May 25, 2017
Postoperative chemotherapy with S-1 plus oxaliplatin versus S-1 alone in locally advanced gastric cancer (RESCUE-GC study): a protocol for a phase III randomized controlled trial
Xiang Hu, Lin Chen, Yian Du, et al.
The Journal of Clinical Investigation
|
February 8, 2022
An Asia-specific variant of human IgG1 represses colorectal tumorigenesis by shaping the tumor microenvironment
Bing Yang, Zhen Zhang, Xiangjun Chen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 19, 2023
Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China
Jian Li, Jun Zhang, Yanqiao Zhang, et al.
The Lancet. Oncology
|
July 12, 2021
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
Xiaotian Zhang, Han Liang, Ziyu Li, et al.
The Lancet. Oncology
|
February 14, 2025
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial
Xiaotian Zhang, Han Liang, Ziyu Li, et al.
Journal of Hematology & Oncology
|
February 16, 2019
Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition)
Jian Li, Ying Yuan, Fan Yang, et al.
Page
of 22